GREEN CROSS WellBeing Corporation (234690) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of GREEN CROSS WellBeing Corporation stock KRW 5,218, price KRW 9,220, that is 43.4% below the price, quality 49 out of 100. Rating: strongly overvalued. Calculated from audited financials with 17 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range 5,685 KRW – 15,100 KRW · fair‑value band 4,921 KRW – 10,391 KRW · the 9,220 KRW price screens above the 5,218 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow GREEN CROSS WellBeing in your weekly email
Every Wednesday you see whether GREEN CROSS WellBeing is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
GC WellBeing Corporation provides personalized nutrition injections in South Korea. The company offers health supplements and food; prescription drugs; and aesthetics, as well as nutritional injections, including vitamins and antioxidants.
Show moreShow less
The company was formerly known as GREEN CROSS WellBeing Corporation and changed its name to GC WellBeing Corporation in April 2026. The company was founded in 2004 and is headquartered in Seoul, South Korea.
Stock analysis
GREEN CROSS WellBeing Corporation (234690) currently trades at 9,220 KRW, while our model-based Fair Value estimate is 5,218 KRW, 43% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 14,628 KRW per share, and 9 of the 17 models we run sit above the 9,220 KRW price.
Bear case: the Dividend Discount group reads lowest at 1,476 KRW, and 8 of the 17 models stay below the price. Data coverage for this calculation is high.
Scenario range: 4,921 KRW (bear) to 10,391 KRW (bull), the price of 9,220 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
GREEN CROSS WellBeing Corporation reported revenue of 165B KRW in FY2025 versus 91.0B KRW in FY2021, a compound +16.0%/yr. Reported net income was 10.0B KRW in FY2025, compounding +10.5%/yr from FY2021.
Key figures
Market cap 165B KRW (≈ $122M) Micro · P/E ratio 29.4 · P/S ratio 0.86 · EPS (TTM) 305.73 KRW · Dividend yield 1.5% · Net margin 2.9% · Return on equity 4.9% · Return on assets (EBIT) 6.7% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 36 out of 100 (low confidence).
What moves the price
The share trades about 39% below its 52-week high and 27% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −43%, 234690 screens richer than that median.
Fair Value models
Bear4,921 KRWFair Value 5,218 KRWBull10,391 KRW
Price 9,220 KRW · Downside -43.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (142.12 KRW per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.58/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+23.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.8%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.2%
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+13.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year+11.9%
Dividend (yield on the price)1.5%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.11.9% vs 8.2%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.2% → 11%
Compare GREEN CROSS WellBeing Corporation with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 559 stocks
Beats the industry median on 10/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score49 · Above median
Fair Value upside−43.4% · Above median
Profitability
Return on equity (12 months)4.9% · Above median
Return on assets4.5% · Top 25%
Net margin (12 months)2.9% · Below median
Operating margin (12 months)8.9% · Above median
Growth and dividend
Revenue growth (quarter YoY)33.8% · Top 25%
Dividend yield (12 months)1.5% · Above median
Balance sheet
Debt / equity0.18× · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/E (12 months)29.4× · Pricier than median
P/B1.47× · Cheaper than median
P/S (12 months)0.86× · Cheapest 25%
EV/EBITDA7.8× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 0
PAST (return on equity)20· sector 0
HEALTH (low debt)91· sector 97
DIVIDEND (yield)30· sector 21
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is GREEN CROSS WellBeing Corporation (234690) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of 5,218 KRW versus a price of 9,220 KRW, about 43% lower (overvalued).
What is the fair value of 234690?
Our model-based fair value for GREEN CROSS WellBeing Corporation is 5,218 KRW (as of Nov 8, 2026), built from audited fundamentals. The current price: 9,220 KRW.
What is the quality score of 234690?
GREEN CROSS WellBeing Corporation has a Quality Score of 49/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for GREEN CROSS WellBeing Corporation (234690)?
Our model-based price target is the fair value of 5,218 KRW (as of Nov 8, 2026) from 17 valuation models. Cautious scenario 4,921 KRW, optimistic scenario 10,391 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the GREEN CROSS WellBeing Corporation stock forecast for 2026?
Our models put fair value at 5,218 KRW, about 43% lower versus a price of 9,220 KRW (overvalued). Cautious scenario 4,921 KRW, optimistic scenario 10,391 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of GREEN CROSS WellBeing Corporation (234690)?
GREEN CROSS WellBeing Corporation reported trailing-twelve-month revenue of about 192B KRW (latest available figure, as of Nov 8, 2026).
Does GREEN CROSS WellBeing Corporation pay a dividend?
GREEN CROSS WellBeing Corporation currently shows a dividend yield of 1.52% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of GREEN CROSS WellBeing Corporation (234690) and when is the ex-dividend date?
GREEN CROSS WellBeing Corporation pays a dividend of 140.00 KRW per share a year, a dividend yield of 1.5%. The last ex-dividend date was Mar 30, 2026. The payout ratio is 45.8% of earnings. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What is the intrinsic value of GREEN CROSS WellBeing Corporation (234690)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For GREEN CROSS WellBeing Corporation it is 5,218 KRW per share (as of Nov 8, 2026), against a price of 9,220 KRW. It is the blended result of 17 valuation models in 7 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is GREEN CROSS WellBeing Corporation stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 234690 trades above its calculated fair value: price 9,220 KRW, fair value 5,218 KRW, a gap of about −43% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 234690?
No. The price is what the market pays today (9,220 KRW); the fair value is what the company's own numbers justify (5,218 KRW). For GREEN CROSS WellBeing Corporation the two are 4,002 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is GREEN CROSS WellBeing Corporation worth?
The market values GREEN CROSS WellBeing Corporation at about 165B KRW (market capitalisation, as of Nov 8, 2026). Per share that is 9,220 KRW; our models calculate a fair value of 5,218 KRW per share.
What do the bullish and bearish scenarios say about 234690?
Our models span a range for GREEN CROSS WellBeing Corporation: cautious scenario 4,921 KRW, base 5,218 KRW, optimistic 10,391 KRW per share (as of Nov 8, 2026, price 9,220 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 234690?
GREEN CROSS WellBeing Corporation trades at a price-to-earnings ratio of 29.4 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 5,218 KRW is built from several models across several years. Median P/E at fiscal year-end, 7 fiscal years (2019 to 2025), reported earnings: 25.3. Other multiples: P/B 1.5, P/S 0.9, EV/EBITDA 7.8.
How solid is the balance sheet of GREEN CROSS WellBeing Corporation (234690)?
Balance-sheet figures for GREEN CROSS WellBeing Corporation (as of Nov 8, 2026): return on equity 4.9%, debt of 0.18 per unit of equity. They feed the Quality Score of 49/100, which measures business quality independently of the share price.
How far is 234690 from its 52-week high?
GREEN CROSS WellBeing Corporation trades at 9,220 KRW, about 39% below its 52-week high of 15,100 KRW and 27% above the low of 7,250 KRW (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 5,218 KRW is for.
Which stocks are comparable to GREEN CROSS WellBeing Corporation?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is GREEN CROSS WellBeing Corporation stock attractive at the current price?
The data as of Nov 8, 2026: price 9,220 KRW, calculated fair value 5,218 KRW (−43%), Quality Score 49/100, from 17 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 234690 calculated?
We run GREEN CROSS WellBeing Corporation through 17 models from 7 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 5,218 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. GREEN CROSS WellBeing Corporation itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of GREEN CROSS WellBeing Corporation (234690)?
The closing price on Nov 9, 2026 was 9,220 KRW. Our model-based fair value is 5,218 KRW, about 43% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with GREEN CROSS WellBeing Corporation right now?
Weak quality (49/100) and above fair value at the same time, the margin of safety is missing on both counts. A fairly wide model range (4,921 KRW to 10,391 KRW) leaves room in how you read the outcome.
Key figures of GREEN CROSS WellBeing Corporation
How large is the market capitalisation of GREEN CROSS WellBeing Corporation (234690)?
The market capitalisation of GREEN CROSS WellBeing Corporation is 165B KRW (≈ $122M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of GREEN CROSS WellBeing Corporation (234690)?
The price-to-sales ratio of GREEN CROSS WellBeing Corporation is 0.86 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of GREEN CROSS WellBeing Corporation (234690)?
Earnings per share at GREEN CROSS WellBeing Corporation are 305.73 KRW (price ÷ EPS = P/E 29.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of GREEN CROSS WellBeing Corporation (234690)?
The dividend yield of GREEN CROSS WellBeing Corporation is 1.5% (payout 45.8%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of GREEN CROSS WellBeing Corporation (234690)?
The net margin of GREEN CROSS WellBeing Corporation is 2.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of GREEN CROSS WellBeing Corporation (234690)?
The return on equity (ROE) of GREEN CROSS WellBeing Corporation is 4.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of GREEN CROSS WellBeing Corporation (234690)?
On an EBIT basis the return on assets of GREEN CROSS WellBeing Corporation is 6.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of GREEN CROSS WellBeing Corporation (234690)?
The operating margin of GREEN CROSS WellBeing Corporation is 8.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at GREEN CROSS WellBeing Corporation (234690)?
Revenue at GREEN CROSS WellBeing Corporation is growing +33.8% versus a year earlier (3y avg +14.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at GREEN CROSS WellBeing Corporation (234690)?
Earnings per share at GREEN CROSS WellBeing Corporation are growing +465% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does GREEN CROSS WellBeing Corporation (234690) generate?
The free cash flow of GREEN CROSS WellBeing Corporation is −467M KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does GREEN CROSS WellBeing Corporation (234690) carry?
The net debt of GREEN CROSS WellBeing Corporation is 62.1B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch GREEN CROSS WellBeing Corporation in the live analysis
One click puts GREEN CROSS WellBeing Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 8, 2026